Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
11C-methylreboxetine is a radiolabeled derivative of reboxetine, specifically labeled with carbon-11, developed as a positron emission tomography (PET) radioligand for imaging the norepinephrine transporter (NET) in the brain. It is used primarily in research settings to visualize and quantify NET distribution and density in vivo. The compound acts as a selective ligand for NET, enabling studies of noradrenergic function in various neurological and psychiatric conditions such as depression, ADHD, drug addiction, eating disorders, and autonomic dysfunction. Its mechanism involves binding to the norepinephrine transporter at adrenergic nerve terminals; it does not have therapeutic effects but serves as an imaging agent to assess NET availability or occupancy by other drugs[1][2][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 11C-methylreboxetine.